New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:12 EDTSGENSeattle Genetics 2014 Adcetris guidance good, says RBC Capital
RBC Capital noted that Seattle Genetics' guidance for 2014 Adcetris sales was in-line with RBC Capital's estimate but below the consensus outlook. RBC Capital thinks the consensus outlook was flawed as it failed to take into account the lack of major catalysts for the drug until possibly late 2014. RBC Capital keeps an Outperform rating on Seattle Genetics.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
16:20 EDTSGENSeattle Genetics sees FY15 Adcetris net product sales $210M-$220M
Subscribe for More Information
16:18 EDTSGENSeattle Genetics reports Q2 EPS (38c), consensus (26c)
Reports Q2 revenue $77.1M, consensus $77.97M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use